58 Views | 41 Downloads
Ujjwal Neogi, Email: ujjwal.neogi@ki.se
Conceptualization and study designing: U.N., Clinical data, and biobank: G.M.I., E.L., M.C.O, C.T.T., H.B. L.E.H., Methodology: F.M., R.B., J.P.d.M., and U.N., Formal analysis (bioinformatics): F.M. and G.D.V.M. and R.B., Formal analysis (experimental): S.S.A., S.K., M.S., A.E., A.V., and S.G., Supervision: R.B., J.P.d.M., and U.N., Resources: U.N. Writing (original draft): F.M., S.S.A, S.K., M.S., and U.N. Writing (review and editing): R.B., G.D.V.M., A.C.B, J.K., K.S., C.L.L., and J.P.d.M., Visualization: F.M., S.S.A, S.K. and U.N., Project administration: G.M.I., L.E.H., and U.N. Funding acquisition: U.N. All authors discussed the results, commented, and approved the final version of the manuscript.
We thank all the study subjects for their participation. Authors acknowledge support from the Proteomics Biomedicum; Karolinska Institute, Solna, for LC-MS/MS analysis. Swedish Metabolomics Centre, Umeå, Sweden is acknowledged for targeted metabolic profiling.
C.L.L. is the co-founder and chief scientific officer for Shift Pharmaceuticals. The remaining authors declare no competing interests.
The study is supported by the Swedish Research Council (2017-01330, 2018-06156 and 2021-01756), Karolinska Institutet Stiftelser och Fonder (2020-01554), and Åke Wiberg Stiftelse grant (M18-0021). Swedish Physicians Against AIDS Foundation (FOb20170004) and Jeanssons Stiftelser (JS2016–0185) to UN. MS acknowledges the support received from the Swedish Physicians Against AIDS Foundation (FOa2019-0020). SG acknowledges support from the Swedish Research Council Establishment grant (2021-03035), the Center for Medical Innovation grant (CIMED-FoUI-093304), Karolinska Institutet Stiftelser och Fonder (2020-02153), and Åke Wiberg Stiftelse grant (M20-0220).
© The Author(s) 2022